Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

Overview of attention for article published in Journal of Clinical Oncology, October 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet
twitter: 13 X users

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 15 X posts from 13 X users, with an upper bound of 117,019 followers.

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018) https://t.co/iQIUgrl2WD

#Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018) https://t.co/iQIUgrl2WD

RT @JCO_ASCO: 😞 Ofranergene obadenovec + weekly paclitaxel did not improve progression-free or overall survival compared to weekly paclitax…

RT @m0370: また知らない薬きた。オフラネルゲン・オバデノベック…😳名前が覚えられる気がしないけれど、別名VB-111とされるウイルスベクターを利用した遺伝子治療薬らしい。／JCO

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 11 additional X posts.